ES2091323T3 - Medios de contraste. - Google Patents

Medios de contraste.

Info

Publication number
ES2091323T3
ES2091323T3 ES91906843T ES91906843T ES2091323T3 ES 2091323 T3 ES2091323 T3 ES 2091323T3 ES 91906843 T ES91906843 T ES 91906843T ES 91906843 T ES91906843 T ES 91906843T ES 2091323 T3 ES2091323 T3 ES 2091323T3
Authority
ES
Spain
Prior art keywords
contrast media
contrast
complexes
rays
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91906843T
Other languages
English (en)
Inventor
Arne Berg
Torsten Almen
Klaus Dieter Krautwurst
Sook-Hui Kim
Pal Rongved
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Application granted granted Critical
Publication of ES2091323T3 publication Critical patent/ES2091323T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Steroid Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Lubricants (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Electric Propulsion And Braking For Vehicles (AREA)

Abstract

LA INVENCION SE REFIERE AL USO COMO AGENTES MEJORADORES DEL CONTRASTE EN LA FORMACION DE IMAGENES MEDICAS, ESPECIALMENTE EN RAYOS X, DE COMPLEJOS MULTINUCLEARES, POR EJEMPLO COMPLEJOS TALES COMO W2O2((MU)2O)2, EN EL CUAL LA ENTIDAD COMPLEJADA COMPRENDE AL MENOS DOS ATOMOS MEJORADORES DEL CONTRASTE.
ES91906843T 1990-03-28 1991-03-27 Medios de contraste. Expired - Lifetime ES2091323T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909006977A GB9006977D0 (en) 1990-03-28 1990-03-28 Compositions

Publications (1)

Publication Number Publication Date
ES2091323T3 true ES2091323T3 (es) 1996-11-01

Family

ID=10673438

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91906843T Expired - Lifetime ES2091323T3 (es) 1990-03-28 1991-03-27 Medios de contraste.

Country Status (18)

Country Link
US (2) US5458869A (es)
EP (2) EP0645146A1 (es)
JP (1) JPH06507147A (es)
AT (1) ATE142508T1 (es)
AU (1) AU645796B2 (es)
CA (1) CA2079212A1 (es)
DE (1) DE69122092T2 (es)
DK (1) DK0521977T3 (es)
ES (1) ES2091323T3 (es)
FI (1) FI924297L (es)
GB (1) GB9006977D0 (es)
HK (1) HK219596A (es)
HU (2) HU9203086D0 (es)
LT (1) LT3535B (es)
LV (1) LV10056B (es)
NO (1) NO923739L (es)
SG (1) SG43931A1 (es)
WO (1) WO1991014460A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
ATE187340T1 (de) * 1991-03-27 1999-12-15 Nycomed Salutar Inc Kontrastmittel
JPH06510759A (ja) * 1991-08-05 1994-12-01 マリンクロッド・インコーポレイテッド 造影剤として使用する重金属クラスター
US5330742A (en) * 1991-08-05 1994-07-19 Mallinckrodt Medical, Inc. Methods and compositions for magnetic resonance imaging
US5364953A (en) * 1992-11-05 1994-11-15 Mallinckrodt Medical, Inc. High relaxivity, paramagnetic, metal clusters for magnetic resonance imaging
GB9407812D0 (en) * 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
US5717121A (en) * 1995-06-07 1998-02-10 Nycomed Salutar, Inc. Preparation and use of contrast agents
GB9601340D0 (en) * 1996-01-23 1996-03-27 Nycomed Salutar Inc Contrast media
WO1997030459A1 (en) * 1996-02-14 1997-08-21 Philips Electronics N.V. X-ray examination apparatus with x-ray filter
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
NZ511677A (en) 1998-12-18 2003-10-31 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7807137B1 (en) 1998-12-22 2010-10-05 University Of Puerto Rico Iron-based contrast agent
US6596259B1 (en) 1998-12-22 2003-07-22 University Of Puerto Rico Metal based cubane structure contained in an octanuclear complex stable over several oxidation states and a method of producing the same
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
WO2001087354A2 (en) 2000-05-17 2001-11-22 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
IL147629A0 (en) 2000-06-01 2002-08-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
CA2427911A1 (en) 2000-11-03 2002-05-10 Bristol Myers Squibb Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
WO2002101847A2 (en) * 2001-06-12 2002-12-19 University Of Florida Method and device for producing near-infrared radiation
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
MXPA04001113A (es) 2001-08-08 2004-07-08 Bristol Myers Squibb Pharma Co Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina.
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
JP4322781B2 (ja) * 2004-11-08 2009-09-02 富士フイルム株式会社 撮像装置
CA2613439A1 (en) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
US20070098641A1 (en) * 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
US9149545B2 (en) * 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
US20070179094A1 (en) 2006-01-31 2007-08-02 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
KR101616139B1 (ko) 2008-02-29 2016-04-27 랜티우스 메디컬 이메징, 인크. 관류 영상화를 포함하는 용도를 위한 조영제
WO2010004460A1 (en) * 2008-07-07 2010-01-14 Koninklijke Philips Electronics N.V. K-edge imaging
CN102458396B (zh) 2009-04-15 2017-05-10 兰休斯医疗成像公司 使用抗坏血酸稳定化放射性药物组合物
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
AU2011213568B2 (en) 2010-02-08 2016-05-12 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
EP2540321A1 (en) 2011-06-30 2013-01-02 Bayer Intellectual Property GmbH Bis Tridentate W3O2 Clusters for X-Ray imaging
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP2733148A1 (en) 2012-11-15 2014-05-21 Bayer Pharma Aktiengesellschaft Tungsten complexes with di-dentate ligands
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468759A (en) 1892-02-09 Gabeiel a
US3860611A (en) * 1972-01-19 1975-01-14 Du Pont Macrocyclic polyether polyols and condensation polymers derived therefrom
US3763188A (en) * 1972-01-19 1973-10-02 Du Pont Spiro(1,1-polyethylenedi(oxymethyl))-3-oxetanes
US3952015A (en) * 1973-11-12 1976-04-20 Carl George Krespan Macrocyclic compounds having oxa and aza linkages in the ring and containing spirooxetane groups
US4079124A (en) * 1976-04-21 1978-03-14 Medi-Physics, Inc. Method of preparing X-ray contrast media containing ores of hafnium, tantalum and tungsten
US4176173A (en) * 1977-07-18 1979-11-27 Medi-Physics, Inc. Radiographic compositions
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4652519A (en) 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
US4826673A (en) 1985-01-09 1989-05-02 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
US4795698A (en) * 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
IE61746B1 (en) 1987-07-16 1994-11-30 Nycomed Imaging As Aminopolycarboxylic acids and derivatives thereof
FR2630547A1 (fr) * 1988-04-22 1989-10-27 Centre Nat Rech Scient Marquage froid de molecules de nature peptidique ou proteique
WO1990003190A1 (en) * 1988-09-29 1990-04-05 Ranney David F Methods and compositions for magnetic resonance imaging
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
US5186923A (en) * 1990-10-10 1993-02-16 Brigham And Womens Hospital Enhancement of cellular accumulation of lipophilic cationic organometallic compounds by reduction of intramembrane potential
JPH06510759A (ja) * 1991-08-05 1994-12-01 マリンクロッド・インコーポレイテッド 造影剤として使用する重金属クラスター

Also Published As

Publication number Publication date
EP0521977B1 (en) 1996-09-11
FI924297A7 (fi) 1992-09-25
ATE142508T1 (de) 1996-09-15
EP0521977A1 (en) 1993-01-13
DE69122092T2 (de) 1997-03-06
HU9203086D0 (en) 1992-12-28
AU7557891A (en) 1991-10-21
HUT69168A (en) 1995-08-28
FI924297A0 (fi) 1992-09-25
EP0645146A1 (en) 1995-03-29
US5458869A (en) 1995-10-17
LTIP609A (en) 1994-12-27
US5614168A (en) 1997-03-25
LT3535B (en) 1995-11-27
WO1991014460A1 (en) 1991-10-03
NO923739L (no) 1992-11-06
LV10056B (en) 1995-02-20
CA2079212A1 (en) 1991-09-29
DE69122092D1 (de) 1996-10-17
GB9006977D0 (en) 1990-05-23
DK0521977T3 (da) 1996-09-30
HK219596A (en) 1997-01-03
JPH06507147A (ja) 1994-08-11
AU645796B2 (en) 1994-01-27
LV10056A (lv) 1994-05-10
SG43931A1 (en) 1997-11-14
NO923739D0 (no) 1992-09-25
FI924297L (fi) 1992-09-25

Similar Documents

Publication Publication Date Title
ATE142508T1 (de) Kontrastmittel
AU591309B2 (en) Taxol derivatives, their preparation and pharmaceutical compositions containing them
GR3005457T3 (es)
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
ATE222244T1 (de) Mono -und multimere verbindungen mit erhöhter relaxation
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
RU95112465A (ru) Пирановые соединения, фармацевтическая композиция, способ получения и промежуточные соединения
ES2118835T3 (es) 2-etil-1h-imidazo(4,5-c)quinolin-4-aminas antiviricas.
RU92016591A (ru) Производные пиримидин нуклеозида
FR2575466B1 (fr) Nouveaux complexes de silicium hexacoordines, leur procede de preparation et leur application
ES8608884A1 (es) Un procedimiento de eliminacion del virus lav.
DK0471718T3 (da) Paracetamolholdigt farmaceutisk præparat
ES472640A1 (es) Procedimiento para preparar seudotrisacaridos
MY102186A (en) Antitumor anthracycline glycosides, their preparation intermediate thereof, and compositions and use thereof
FR2446279A1 (fr) Cis- et trans-3-aryloxy-4-hydroxypyrrolidines et leurs derives, utiles notamment en medecine veterinaire comme antidepresseurs
FR2383152A1 (fr) Procede de preparation du 2-methyl-3-prenyl-4,5,6-trimethoxyphenol
ATE27279T1 (de) (1,2-diphenyl-ethylendiamin)-platin(ii)komplexverbindungen.
JPS5234923A (en) Novel antimicrobial agents for non-medical use
ATE161732T1 (de) In cyclodextrinen eingeschlossene steroide
ATE92070T1 (de) Azachromanderivate.
FR2368489A1 (fr) Derives de la clavuline, leur procede de preparation et leur application en therapeutique
DE3769287D1 (de) Heilmittel gegen leishmaniose.
ZA908679B (en) (1r,2r)-2-(3-pyridyl)-tetrahydrothiopyran-2-carbothioamide 1-oxides,process for their preparation and pharmaceutical compositions containing them
Seo Recommendations for the Improvement of the Medical Licensing Examination
FR2385703A1 (fr) Nouveaux derives d'imidazole et complexes metalliques de ceux-ci, procede de preparation desdits derives et application sous forme d'agents fongicides

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521977

Country of ref document: ES